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Response to original research article, in press, corrected proof,
‘‘Long term toxicity of a Roundup herbicide and a Roundup-
tolerant genetically modiﬁed maize’’ Available online 19
September 2012, Gilles-Eric Séralini, Emilie Clair, Robin Mesnage,
Steeve Gress, Nicolas Defarge, Manuela Malatesta, Didier
Hennequin, Joël Spiroux de Vendomois.
We have reviewed the aforementioned article and have found
numerous deﬁciencies in the way the study was designed, and in
the manner in which the data were presented and analyzed. As a
consequence of these deﬁciencies, the study cannot be used to
support any conclusions regarding the safety of NK603 glyphosate
tolerant maize and Roundup herbicide.1
1. Experimental design
The authors of this study assert that it was conducted in a GLP
environment and according to OECD guidelines. They did not follow
OECD GLP guidelines nor OECD testing guideline (TG) 453 (2009)
for conduct of a combined chronic toxicity/carcinogenicity study.
OECD GLP’s require ‘‘Detailed information on the experimental
design, including a description of the chronological procedure
[e.g., start date, end date] of the study, all methods, materials and
conditions, type and frequency of analysis, measurements, observa-
tions and examinations to be performed, and statistical methods to
be used (if any)’’ and . . . ‘‘The study should be conducted in accor-
dance with the study plan’’. Apparently, the authors’ original intent
was not to conduct a carcinogenicity study ‘‘. . .we had no reason to
settle at ﬁrst for a carcinogenicity protocol using 50 rats per group.’’
(Séralini et al., 2012), but at some point during the in-life phase,
they changed the purpose of the study by extending it to 2 years
to assess potential carcinogenicity. Assuming they had a protocol
at the start of the study, they did not follow it as they substantially
altered the purpose and the design of the study while it was in pro-
gress. This should be considered a violation of GLP guidelines as the
study was not conducted in accordance with the original study
plan. If they wanted to carry out a carcinogenicity study, they
should have terminated the existing study, and prepared a new
study plan adapted from OECD TG 453. They did recognize, as
stated above, that they needed a larger number of animals
(a minimum of 50 rats/sex/group) for a carcinogenicity study,
instead of the 10 rats/sex/group that they had in their existing
study. For reasons which will be discussed later, their study did
not have enough animals to draw any meaningful conclusions.
Rodent carcinogenicity studies must be sufﬁciently powered
not only to detect an increased incidence of rare tumor types,0278-6915  2012 Elsevier Ltd.
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Open access under CC BY-NC-ND license.but also to discriminate treatment-related effects from spontane-
ous, or background, incidence of common tumor types. For this
reason, US (US EPA, 1998; FDA, 2006) and OECD (1995a) regulatory
guidelines for the conduct of carcinogenicity studies in rodents
specify the use of at least 50 animals per sex per treatment group.
In addition, OECD states that ‘‘it is unlikely that a regulatory
authority would ﬁnd a study using a lower core number of animals
per sex and per group acceptable for regulatory purposes, since a
sufﬁcient number of animals should be used so that a thorough
biological and statistical evaluation can be carried out.’’ (OECD,
1995b). OECD further states that ‘‘for strains with poor survival
such as SD rats, higher numbers of animals per group may be
needed in order to maximize the duration of treatment (typically
at least 65/sex/group).’’(OECD, 1995b). For this reason, the US
EPA speciﬁes that survival in any group should not fall below
50% at 18 months or below 25% at 24 months (US EPA, 1998), while
the US FDA speciﬁes survival of a minimum of 25 rats per sex per
group at study termination (FDA, 2006). The SD rat has been
widely used in toxicology research, including numerous chronic
studies, but these studies employ many more animals than used
by the authors in consideration of their lower survival rate and
high background tumor rates, especially mammary tumors in
females.2. Statistical analysis and presentation of data
The authors have a history of inappropriate application of sta-
tistical methods to analyze toxicology data (Séralini et al., 2007;
Spiroux de Vendomois et al., 2009) which has been criticized by
regulatory agencies and other experts (EFSA, 2007, 2010; FSANZ,
2009a,b; HCB, 2009; Doull et al., 2007). There are numerous prob-
lems in the way the data were statistically analyzed in this study.
For example, in Table 3, mean values are not presented for each
group and sex to allow comparison of measured parameters. Con-
trol data are not presented. Instead, the authors used a statistical
method that is not traditionally used to present toxicology data,
a multivariate technique called Partial Least Squares Discriminant
Analysis (PLS-DA). Mean differences (%) of variables (discriminant
at 99% conﬁdence intervals) were presented to investigate the rela-
tionship among 48 blood and urine measurements relative to the
different treatment groups. PLS-DA can be used to identify patterns
in the data and to develop a function which can be used to discrim-
inate between the groups. However, any differences between
groups must be further evaluated for toxicological relevance. Pre-
sentation of the data in this manner does not lend itself to straight-
forward interpretation of the study ﬁndings.
In Fig. 5, the same PLS-DA procedures were followed with jack-
knifed conﬁdence intervals at 99% conﬁdence level. This procedure
may be familiar to statisticians, but it is not commonly used to
present toxicology data and is difﬁcult to interpret, particularly
when the data used to construct these graphs are not presented.
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sured parameters fall within 99% conﬁdence intervals with the
exception of serum and urine electrolytes. Unfortunately, no data
were provided from other intervals when these data were col-
lected to determine if the same patterns were evident. No lab his-
torical data were provided to put these data in perspective. As
stated earlier, just because one can discriminate between the
groups, it does not make the result toxicologically relevant. There
was no presentation of actual statistical analysis to compare the
means for each measured parameter.
To determine if there are patterns of differences in toxicologi-
cally related ﬁndings, the toxicologist expects to see the actual
mean data for each parameter/group and the standard deviation
and the control data should also be provided for comparison. The
test and control values for measured parameters should also be
compared to the historical control data from the testing laboratory
and/or the literature to determine if differences were within or
outside of the normal range. As presented, the reader has no way
of determining whether the conclusions drawn by the authors
are supported by the actual data, or are merely statistical anoma-
lies resulting from non traditional analysis. The manuscript con-
tained ﬁgures with graphs that were difﬁcult to read because
lines overlapped, and percent variations were presented rather
than the mean test and control data which is the more standard
practice in presenting toxicology data. For instance, incidences of
1 vs. 2 or 5 vs. 10 both represent a change of 100%, however, these
absolute values would likely result in different conclusions.
The same criticism can be made for Fig. 2 and Table 2 where the
data are not broken out in the tables so the reader can actually see
what changes were observed for each group. The incomplete pre-
sentation of study data, which was acknowledged by the authors
– ‘‘all data cannot be shown in one report, and the most relevant
are described here-’’ precludes meaningful review and evaluation
of study results (Seralini et al., 2012). For example, histopathology
incidence/severity data are not presented (e.g., Table 2); nor is any
laboratory historical control data provided to help interpret the
biological relevance of clinical pathology and histopathology ﬁnd-
ings. Did the testing laboratory have historical pathology data for
chronic studies? The generalized statements of increased liver dis-
orders cannot be veriﬁed without presenting the actual data in a
table to review.
3. Misinterpretation of study ﬁndings
3.1. Mortality data
The authors stated that male and female rats in all treatment
groups had more and earlier deaths than the controls. However,
they acknowledge that mortality was not dose related. For exam-
ple, according to Fig. 1, low dose males fed NK603 grain (un-
sprayed with Roundup) had more early deaths and overall
mortality (5/10), while the mid and high dose group mortality near
the end of the study was similar to controls (3/10). In the male
group fed NK603 (sprayed with Roundup), the mid dose males
had more early deaths (4/10), followed by the low dose, and the
high dose had the lowest mortality of the NK603 fed groups. For
rats administered Roundup in drinking water, high dose males
had the lowest mortality compared to the other Roundup treated
groups. Similar examples of lack of dose relationships in mortality
were observed in the treated female groups. In consideration of the
fact that there were 9 treatment groups compared to one control
group, some variability in mortality between groups would be ex-
pected by chance and could well have explained the distribution of
mortality in the study. Given the small group size of 10 rats/sex/
group, differences in mortality between groups generally involved
only a few animals, and it would be difﬁcult to interpret thebiological relevance of such small differences. If dose is not impor-
tant in this design, it is a 90% probability that one of the test groups
would numerically have the highest incidence of mortality.
The authors should have used the adjusted analysis of survival
to determine if there were more dead animals in the treated
groups compared to the control group, and if there were earlier
deaths in the treated groups than in the control group. The most
useful statistical approach used to compare survival between
groups (not followed by the authors) is the following procedure:
Adjusted survival rates are estimated using Kaplan Meier estima-
tion procedures (Kaplan and Meier, 1958). Kaplan Meier estimates
are calculated separately for each sex and treatment group. Mor-
talities which are the result of animals dying following accidents
(accidental trauma, died during anesthesia, killed at study director
request) or at scheduled sacriﬁce have to be considered as cen-
sored observations. In a second step, statistical signiﬁcance of dif-
ferences in survival rates between treated and control groups and
dose related trend in survival could be assessed using Cox’s and
Tarone’s tests on life table data.
The authors did not indicate whether the tumor classiﬁcation
was done according to the PETO codes (incidental, fatal, observed
in life). At least a PETO analysis or a mortality-adjusted analysis
for tumor incidences should have been performed.
The authors reported higher survival than is typically reported
for female Harlan SD rats in 2-year studies. According to Fig. 1,
only 2 of 10 animals died before the end of the study resulting
in survival rate of 80%. The SD rat is known to exhibit low and var-
iable survival after 18 months of age (Nohynek et al., 1993;
Keenan, 1996). Therefore, as discussed earlier, many more animals
than 10/sex/group would be needed to ensure that there would be
a sufﬁcient number surviving to the end of the study. This would
be needed to conduct a meaningful statistical analysis and to draw
solid conclusions regarding biological signiﬁcance. Average
survival in 7 NTP 2-year studies with female Harlan SD rats was
reported to be 41.5% (Brix et al., 2005). In a later published review,
a survival rate of 42.5% was reported for 2-year studies conducted
by the NTP with female Harlan SD rats (Dinise et al., 2010). Charles
River SD female rats were reported to have a 2-year survival
ranging for 20–60% with an average of 37% (Giknis and Clifford,
2004). Given the high survival rate of female rats in this study, it
would be very interesting to learn what the historical 2-year
survival rate was for female Harlan SD rats in the testing facility
that performed the authors’ study. No historical control data from
the testing laboratory were provided for any of the parameters
measured.
3.2. Tumor ﬁndings
The manuscript misleads readers by attributing the tumors ob-
served in the study to treatment with NK603 grain administered in
the diet or Roundup via drinking water. For example, the authors
failed to acknowledge that mammary and pituitary tumors ob-
served in this study are very common in untreated female SD rats
fed ad libitum for 2 years. They included color pictures of treated
rats bearing large mammary tumors, but did not did not include
photos of control rats or acknowledge that similar tumors were
also observed in controls. Mammary gland tumors are observed
not only in older control female SD rats, but can also appear early
in a chronic study (Durbin et al., 1966). Older control female Har-
lan SD rats have a high background tumor incidence, e.g., for the
mammary gland, adenoma 3%; adenocarcinoma 11%; ﬁbroade-
noma 71%; adenomas of the pituitary gland are reported at an inci-
dence of approximately 41% (Brix et al., 2005). Pituitary adenomas
(prolactinomas) contribute to the development of mammary
tumors in SD rats. These historical observations can account for
the ﬁnding of one mid dose female in the mid dose NK603 group
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the other mammary and pituitary tumors observed in both control
and treated female groups later in the study. In Table 2, the authors
report that treated females had more mammary tumors/rat than
controls. However, they do not follow the standard convention of
listing the tumor types conﬁrmed pathologically for each group
and incidence of animals in each group bearing those tumors.
The authors have instead combined all of the tumors together/ani-
mals in a group so the reviewer cannot compare the actual tumor
data by type between groups. The absence of a dose relationship in
some of tumor ﬁndings was evidenced by the high dose Roundup
group females having lower incidence of total tumors than the low
dose group. The authors also noted that the size and number of tu-
mors were not proportional to the treatment dose. Since the low
dose of Roundup administered in drinking water was orders of
magnitude lower than the high dose, yet the lowest dose had a
higher tumor incidence, the data are clearly not dose related and
most likely reﬂect normal variability in the incidence of common
tumors that have a high background rate.
3.3. Other pathologic ﬁndings
Other pathological changes reported by the authors as treat-
ment-related are similarly prevalent in the aged SD rat, including
multiple diet-related disorders, degenerative renal and endocrine
diseases, etc. (Keenan, 1996).
The authors reported treatment-related liver and kidney
pathologies in males. As evidence of kidney effects, they refer to
Table 2 where the incidence of chronic progressive nephropathy
(CPN) was 3/10 control animals compared to 7/10 animals in the
high dose NK603 group (non-sprayed). However, they neglect to
mention that the incidence of CPN in the NK603 sprayed groups
and the Roundup groups are similar and that the high dose groups
had the lowest incidence. They did not report the severity grades of
CPN to learn whether it was increased in a dose related manner. A
similar pattern was observed for liver ﬁndings, although Table 2
does not state what the liver pathologies were. This is an unaccept-
able way to present pathology data. As the study progressed, there
were insufﬁcient numbers of male animals left to make meaningful
comparisons for liver and kidney pathology changes. The authors
reported that only 3/10 control male animals were found to have
CPN. This pathologic change has been reported to occur commonly
in male rats (Hard and Khan, 2004) and in one chronic rat study
with Harlan SD male rats, the incidence was 100% in control male
rats (Petersen et al., 1996). One might have expected a higher
incidence of CPN in control males. In Petersen et al. (1996), CPN
accounted for 48% of the early deaths in control males. Given the
very high background incidence of this disease, and the fact that
9 treatment groups are being compared to one control, some
variation in the number of CPN afﬂicted animals would be ex-
pected between groups. Unfortunately, no historical control lab
data for pathologic lesions were made available for comparisons.
The author’s misquoted the aforementioned Hard and Khan
(2004) publication stating that only elderly rats are sensitive to
CPN whereas the publication states ‘‘Although usually regarded
as a disease of the aging rat, incipient lesions of CPN are detectable
in hematoxylin and eosin (H&E)-stained sections of male rat
kidney at least as early as 2 months of age.’’
The authors have asserted in previous publications (Séralini
et al., 2007; Spiroux de Vendomois et al., 2009) that GM crops
cause liver and kidney pathologies based on their statistical re-
analysis of published 90 day feeding studies mentioned earlier.
However regulatory agency scientists and other experts have not
supported these claims and ﬁnd no evidence of treatment related
liver or kidney pathology changes in any of these studies (EFSA,
2007, 2010; FSANZ, 2009a,b; HCB, 2009; Doull et al., 2007).The authors also presented clinical pathology data in Fig. 5 and
Table 3 which they interpreted to show changes in serum and ur-
ine electrolytes supporting their hypothesis of kidney damage.
However, as stated earlier, the presentation of the data does not
permit comparison of the actual measured values to controls since
control data were not presented. No actual mean data for the urine
and serum electrolytes were provided to provide comparisons be-
tween test and control groups as well as historical control ranges
for these parameters from the testing laboratory.
3.4. Glyphosate safety
Since a number of the changes observed in this study were not
dose related, the authors conjectured that these ﬁndings were hor-
mone and sex dependent, and exhibited a threshold response at a
single dose, which happened to be the lowest dose tested. They
state categorically that Roundup is a ‘‘sex endocrine disruptor’’
that contributed to the tumors and other pathologies observed in
their study, with no scientiﬁc basis for this statement.
To respond to these allegations, it is necessary to review what is
known about the potential toxicology of Roundup and its active
ingredient, glyphosate. WEATHER MAX herbicide is a typical
commercial Roundup formulation that is essentially the potassium
salt of glyphosate with 10% surfactant in water. The category of
surfactant in this Roundup™ formulation was evaluated by the
US EPA in 2009 and was considered acceptable for this use in pes-
ticide products based on the results of multiple repeat dose stud-
ies, including reproductive and developmental toxicology (US
EPA, Federal Register, 2009a). It should further be noted that con-
sumers have regular exposure to surfactant materials in the form
of shampoos, soaps, and cleaning products. These are similarly
not believed to present reproductive/endocrine risks, but in any
event, exposure to surfactant residues as a result of pesticide expo-
sure represents a very small portion of human surfactant exposure.
There is no evidence that the surfactant categories used in Round-
up are endocrine disruptors (Williams et al., 2012).
Glyphosate is a structural derivative of the amino acid glycine,
it has a methylphosphonate group at the amino terminus. Amino
acids are not endocrine disruptors. Extensive in vitro (test-tube)
and animal data indicate glyphosate is not an endocrine disrupter.
Although glyphosate was included in the EPA’s initial substances
for the endocrine disrupter screening program, EPA has stated
‘‘This list should not be construed as a list of known or likely endo-
crine disruptors. Nothing in the approach for generating the initial
list provides a basis to infer that by simply being on this list these
chemicals are suspected to interfere with the endocrine systems of
humans or other species, and it would be inappropriate to do so.’’
(US EPA, Federal Register, 2009b). Furthermore, the EPA speciﬁ-
cally rejected the assertions presented in Richard et al. (2005) that
glyphosate was an endocrine disruptor based on (i) exceedingly
high doses, over 40 times the maximum acceptable concentration
for this study type, (ii) failure to actually meet the criteria for a po-
sitive result in this assay, despite the high dosing, and (iii) lack of
demonstrated study proﬁciency including no concurrent positive
controls to demonstrate assay validity (US EPA, 2011).
The cited in vitro studies conducted by the Seralini laboratory
have repeatedly been reviewed and considered irrelevant to
in vivo exposures by numerous authoritative bodies. In vitro test
systems are not appropriate for evaluating surfactants due to their
physico-chemical properties impairing cell membrane integrity,
including mitochondrial membranes. The selective use of litera-
ture, without consideration of research (Levine et al., 2007) dem-
onstrating that the effect is the result of surfactant impacts on
mitochondrial membranes and occurs with a range of surfactants,
including those with much greater consumer exposure, demon-
strates consistent and undeterred bias in the authors’ publication
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relevance of the Seralini team’s research to human health risk
assessment; such as, French Ministry of Agriculture and Fish, Com-
mittee for Study of Toxicity (2005), French Agency for Food Safety,
AFSSA (2009), and BfR (2009).
The safety of glyphosate has been assessed in numerous
chronic/carcinogenicity studies conducted by various registrants
over the years, as glyphosate has gone off-patent, and none of
these studies have found any evidence that glyphosate causes
mammary cancer or any other kind of cancer. The WHO/FAO Joint
meeting on Pesticide Residues reviewed several glyphosate toxi-
cology data sets including ﬁve chronic rat and two chronic mouse
studies in 2004, concluding no evidence of carcinogenicity (WHO/
FAO, 2004a,b). The US EPA’s classiﬁcation as ‘‘Group E carcinogen
(signiﬁes evidence of non-carcinogenicity in humans)’’ is based
on review of two chronic rat and one chronic mouse study (US
EPA, 1993) and the EU Commission conclusion of ‘‘no evidence of
carcinogenicity’’ is based on review of four chronic rat and four
chronic mouse studies (EC, 2002). The dosages used covered a
broad range of exposures, and the highest dosages used were much
greater than those tested by the authors and many, many times
higher than human potential exposures since glyphosate can be
dosed at high levels in animals as it is not very toxic. Thus, the
overwhelming weight of evidence indicates glyphosate is not an
animal carcinogen.
In the authors’ chronic study, there were 20 control and 180
test rats (sexes combined) divided into 9 different groups. In con-
trast, the FAO/WHO (2004b) review of glyphosate referenced
above included a total of 2330 rats in 5 chronic rat studies. In-
cluded in this number were 540 control rats. In the recent EU An-
nex 1 Renewal dossier submitted in Europe for glyphosate, there
were 9 chronic rat studies with a total of 3938 rats (additional
studies from new manufacturers of glyphosate) of which 942 were
control rats. The new chronic studies also reported no evidence of
carcinogenicity. The authors failed to mention the many toxicology
studies carried out on glyphosate that conﬁrm it does not cause
cancer or liver and kidney pathologies as reported by the authors.
The authors did not acknowledge that there was another
chronic rat study carried out with glyphosate tolerant soybeans
where the investigators reported no evidence of treatment-related
adverse effects including cancer. This was a more robust study as it
contained 50 rats/sex/group (Sakamoto et al., 2008).
The authors also reported blood hormonal analyses (estradiol,
testosterone), although no speciﬁed times during the day were gi-
ven for blood sampling. Hormonal parameters exhibit signiﬁcant
diurnal variations. For this reason, proper analysis must include
the historical variation observed in the performing laboratory,
but no information was provided in this study – a very signiﬁcant
omission. Secondly, the results of hormone analysis on just one day
are not representative of what is going on throughout the study,
especially for hormones characterized by episodic secretion. No
dose–response relationship in hormone levels was observed. It is
not possible to correlate the hormone levels observed at one time
point in this study with the development of mammary tumors as
proposed by the authors. Further, in rats, the main mode of action
for development of mammary tumors is an increase of prolactin le-
vel and then an increase of pituitary tumors. Thus, we question the
increase of tumor incidence with concomitant decrease of estradiol
and increase of testosterone. It is not logical.
The authors also propose another hypothesis to explain their
data, that the introduction of the CP4 EPSPS enzyme that imparts
tolerance to topically applied glyphosate caused metabolic distur-
bances in secondary metabolites. In particular, they report a statis-
tically signiﬁcant reduction in the levels of secondary metabolites
caffeic and ferulic acid in the NK603 diets. The levels of ferulic acid
in the NK603 diet (composition of diets not speciﬁed) were re-ported to be from 735 to 889 ppm compared to 1057 ppm in the
control. Since they report differences in the diets, it is unclear
whether other ingredients in the diet could have contributed to
these differences. No details were provided on the dietary compo-
nents in the formulated diets except the level of NK603 and control
grain that were added.
In a published study summarizing compositional analysis of
NK603 grain, Ridley et al. (2004) reported no differences in ferulic
acid levels between NK603 and its control comparator. The range
of grain ferulic acid was 1500–2500 ppm (mean 2000 ppm) for gly-
phosate sprayed NK603 maize. Control maize levels ranged from
1700 to 2300 ppm (mean 2000 ppm). Ferulic acid levels can vary
considerably in non GM maize ranging from 174 to 3540 ppm
(fw) with a mean of 1950 ppm (ILSI Crop Composition Data Base,
v4.2, 2011).
3.5. Questions on EM methods
The authors reported ﬁnding glycogen dispersion or appearance
of lakes, etc. following electron microscopic (EM) examination of
livers from animals fed NK603 (sprayed) or animals administered
Roundup in drinking water. Manuela Malatesta, who performed
the EM work described in this publication, has been previously
criticized for technical deﬁciencies regarding EM work carried
out in mice fed presumably glyphosate tolerant soybeans
(Williams and DeSesso, 2010).
The authors do not describe the fed/fast state of the animals at
the time of terminal killing. The liver is a dynamic organ that stores
and releases glycogen quickly. Different feeding states of animals
in the same treatment/control group could give samples that look
like all three micrographs in Fig. 4.
The authors’ statements regarding the quality of the methods
used are not backed up by the description in the publication. The
electron microscopy is based on an unknown number of samples
from one control, one low dose and one mid dose animal. These
animals were reported to exhibit the greatest degree of liver
pathology yet the authors report no procedures to ensure a bal-
anced investigation of treated versus control samples. The micro-
graph of the control portion of a hepatocyte shows tissue from
an area 13  13 l. The total area is of the picture is the area is
about the size of 3 red blood cells. This is a very small amount of
tissue on which to draw a conclusion.
The most signiﬁcant issues with the limited amount of selective
microscopy used to support the authors’ contentions relate to the
anatomy of the liver. The liver is a large organ (the largest internal
organ in the body) that has great diversity in its anatomy. If a sam-
ple were taken from the edge of the liver and were compared to a
sample from the middle of the same liver near the entry of the por-
tal vein, the cells would look different. The fact that the tissue was
diced and not put in ﬁxative precludes knowing whether the sam-
ples were taken from the same section of organ across all treat-
ment groups.
Not only is the liver diverse across the organ, but also within its
internal structure. One of the ways histologists describe the orga-
nization of the liver is by speaking about the liver lobule. For the
purpose of this discussion, the method that describes a liver lobule
as liver cells surrounding the central vein of the lobule will be
used. In that description, the lobule is conceptualized as consisting
of three concentric layers of cells that surround the central vein in
a hexagonal shape. (There are thousands of these lobules in a lobe
of the liver.) The arterial supply to the liver lobules is derived from
arteries at the angles of the hexagon. In the fed state, glucose ar-
rives via the arteries and is processed into glycogen by the hepato-
cytes. The outer layer takes up glycogen ﬁrst; later the middle layer
will take up glycogen; and ﬁnally, if sufﬁcient glucose is left, glyco-
gen will be found in the inner layer. Glycogen stores are depleted
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glycogen-depleted most of the time; under fed conditions the out-
er layer has many glycogen granules; and the middle layer is inter-
mediate in appearance. One could ﬁnd all three of the conditions
illustrated in Fig. 4 by looking within a single (or several) lobules
from the same tissue sample. Mitochondria also have various
appearances depending on their proximity to the oxygen rich
arteries or oxygen depleted central vein.
In the absence of rigorous morphometric analysis that also ac-
counts for the anatomy of liver lobules, the photographs in Fig. 4
have neither context nor toxicological meaning,
In Fig. 3, necrotic foci are considered to be either clear focus or
basophilic focus: which is scientiﬁcally wrong as these foci are pre-
neoplastic entities. Moreover basophilic focus with atypia is not
part of the international microscopic nomenclature. Furthermore,
microscopic pictures cannot be interpreted properly (bad quality
and low magniﬁcation). Macroscopic pale spots cannot be corre-
lated to a necrotic focus.
3.6. Questions regarding materials and methods, missing data
No information was provided regarding the identiﬁcation of the
near isoline to conﬁrm that it had similar genetic background. The
location, growing conditions, watering and agrochemical treat-
ments of crops were not detailed. This could have had an impact
on the composition of crops and then on the outcome of the study.
No information was provided on the potential mycotoxins that
might be found in the control and NK603 treated crops and might
have impacted the study. Was the grain stored adequately during
the 2 years of the study to minimize mold growth and mycotoxin
contamination? How often were batches made, were they checked
periodically by PCR methods to conﬁrm that the control diets con-
tained only control and not test maize and visa versa. How were
the diets stored?
No information was provided regarding (a) detailed diet formu-
lation and manufacturing processes as well as nutrient composi-
tion of the diets (b) drinking water contaminant analysis
methods or results (c) homogeneity, stability or concentration of
ROUNDUP in drinking water formulations. How often were drink-
ing water solutions produced?
The control group was reported to contain 33% non-GM maize
in the diet. Low and mid dose NK603 groups (sprayed, unsprayed)
reportedly contained 11% and 22% NK603 maize grain. Results
from the low and mid dose groups cannot be compared to the con-
trol group if they had lower levels of corn grain added to the diets.
There was no drinking water control group for comparison to
the treatment groups fed different concentrations of Roundup in
drinking water.
3.7. Missing data
In Table 1, the study design represents that behavioral studies
were conducted twice. There is no mention of behavioral studies
in methods and no results were presented.
Ophthalmology was reported to be conducted twice. There is no
mention of ophthalmology evaluations in the methods and no re-
sults were presented.
Microbiology was to be conducted in feces and urine. There is
no mention of microbiology evaluations in the methods and no re-
sults were presented.
Evaluation of glyphosate residues in tissues was reported to be
performed, but no information on methods or data generated was
provided. Tissue residues are usually evaluated after administra-
tion of radiolabelled test materials under toxicokinetic testing
guidelines such as OECD 417 (OECD, 2010). For glyphosate, the re-
sults of such studies have been evaluated by the WHO/FAO JointMeeting on Pesticide Residues (2004a,b) and other regulatory
agencies around the world.
Evaluation of the transgene in tissues was reported. There was
no mention of transgene analysis in methods or results sections,
with the exception of conﬁrmation NK603 in maize grain and for-
mulated diets by qPCR.
Food, water consumption and body weights were reported to be
measured in the study, but the data were not presented in the
manuscript. This is basic information that should be provided for
a chronic feeding study to assess potential adverse effects.
Clinical pathology data was reported to be measured at eleven
different intervals during the study but only data from month 15
was summarized, and not in a manner it could be easily reviewed.
Further, data from the two sexes was presented differently. No his-
torical control information from the testing laboratory for mea-
sured parameters was presented.
4. Conclusion
As a result of methodological failures, incomplete data presen-
tation, and lack of proper statistical analysis, Seralini et al.’s con-
clusions regarding NK603 and/or Roundup cannot be supported
by the presented data. Indeed, the fundamental ﬂaw in regards
to the number of animals employed makes it highly unlikely that
any of the purported ﬁndings can be statistically supported using
standard approaches to analysis even if more data were to be pro-
vided by the authors.
Conﬂict of Interest
The authors are employees of Monsanto Company.References
Afssa, 2009. Avis de l’Agence française de sécurité sanitaire des aliments relatif au
glyphosate et aux préparations phytopharmaceutiques à base de cette
substance active. Afssa – saisine n2008-SA-0034 – Glyphosate. le 26 mars
2009. Available from: <http://www.afssa.fr/Documents/DIVE2008sa0034.pdf>.
Bfr, 2009. Comment by Bfr on the publication by Gasnier et al. (2009): Glyphosate-
based herbicides are toxic and endocrine disruptors. 6-2501-5267594.06
August 2009.
Brix, A.E., Nyska, A., Haseman, J.K., Sells, D.M., Jokinen, M.P., Walker, N.J., 2005.
Incidences of selected lesions in control female Harlan Sprague-Dawley rats
from two-year studies performed by the National Toxicology Program. Toxicol.
Pathol. 33, 477–483.
Dinise, G.E., Peddada, S.D., Harris, S.F., Elmore, S.A., 2010. Comparison of NTP
historical control tumor incidence rates in female Harlan Sprague Dawley and
Fischer 344/N rats. Toxicol. Pathol. 38, 765–775.
Doull, J., Gaylor, D., Greim, H.A., Lovell, D.P., Lynch, B, Munro, I.C., 2007. Report of an
Expert Panel on the reanalysis by Seralini et al. of a 90-day study conducted by
Monsanto in support of the safety of a genetically modiﬁed corn variety (MON
863). Food Chem. Toxicol. 45(11), 2073–2085. Available from: <http://
www.sciencedirect.com/science/article/pii/S0278691507003249>.
Durbin, P.W., Williams, M.H., Jeung, N., Arnold, J.S., 1966. Development of
spontaneous mammary tumors over the life-span of the female Charles River
(Sprague-Dawley) rat: the inﬂuence of ovariectomy, thyroidectomy and
adrenalectomy–ovariectomy. Cancer Res. 26 (1), 400–411.
EFSA, 2007. EFSA reafﬁrms its risk assessment of geneticallymodiﬁedmaizeMON863.
Available from: <http://www.efsa.europa.eu/en/press/news/gmo070628.htm>.
EFSA, 2010. EFSA response to de Vendomois et al. (see Annex 1 of the document
linked below). Available from: <http://www.efsa.europa.eu/en/events/event/
gmo100127-m.pdf>.
European Commission, 2002. Report for the Active Substance Glyphosate, Directive
6511/VI/99, January 21. Available from: <http://ec.europa.eu/food/fs/sfp/ph_ps/
pro/eva/existing/list1_glyphosate_en.pdf>.
FDA, 2006. Carcinogenicity Studies with Rodents. Redbook 2000: C.6. January 2006
(Chapter 4).
FSANZ (update) 2009a. Feeding studies and GM corn MON863. Available from:
<http://www.foodstandards.gov.au/scienceandeducation/factsheets/factsheets/
feedingstudiesandgmc5604.cfm>.
FSANZ response to de Vendomois et al., 2009b. A comparison of the Effects of Three
GM Corn Varieties on Mammalian Health. Int. J. Biol. Sci. 5(7), 706–726.
464 Letter to the editor / Food and Chemical Toxicology 53 (2013) 459–464Available from: <http://www.foodstandards.gov.au/scienceandeducation/
factsheets/factsheets2009/fsanzresponsetoseral4647.cfm>.
Giknis, M.L.A., Clifford, C.B., 2004. Charles River Laboratories. Compilation of
spontaneous neoplastic lesions and survival in Crl:CD (SD) rats from control
groups.
Hard, G.C., Khan, K.N., 2004. A contemporary overview of chronic progressive
nephropathy in the laboratory rat, and its signiﬁcance for human risk
assessment. Toxicol. Pathol. 32, 171–180.
HCB, 2009. French High Council of Biotechnologies response to de Vendomois as
translated by UK ACNFP (Advisory Committee on Novel Foods and Processes).
Available from: <http://www.food.gov.uk/multimedia/pdfs/acnfp9612a2>.
ILSI, 2011. Crop composition database, version 4.2. International Life Sciences
Institute, Washington, DC. Available from: <http://www.cropcomposition.org/>.
Kaplan, E.L., Meier, P., 1958. Nonparametric estimation from incomplete
observations. J. Am. Stat. Assoc. 53, 457–481.
Keenan, K.P., 1996. Commentary: the uncontrolled variable in risk assessment: ad
libitum overfed rodents – fat, facts and ﬁction. Toxicol. Pathol. 24, 376–383.
Levine, S.L., Han, Z., Liu, J., Farmer, D.R., Papadopoulos, V., 2007. Disrupting
mitochondrial function with surfactants inhibits MA-10 Leydig cell
steroidogenesis. Cell Biol. Toxicol. 23 (6), 385–400.
Nohynek, G.J., Longeart, L., Geffray, B., Provost, J.P., Lodola, A., 1993. Fat, frail and
dying young: survival, body weight and pathology of the Charles River Sprague-
Dawley-derived rat prior to and since the introduction of the VAFR variant in
1988. Human Exp. Toxicol. 12, 87–98.
OECD, 1995a. Carcinogenicity Studies. OECD Guideline for the Testing of Chemicals,
No. 451, adopted 07 September 2009.
OECD, 1995b. Guidance Document 116 on the Conduct and Design of Chronic
Toxicity and Carcinogenicity Studies, Supporting Test Guidelines 451, 452 and
453, second ed. OECD Series on Testing and Assessment, No. 116, adopted 13
April 2012.
OECD,417 (adopted 22 July, 2010) Toxicokinetics. OECD Guidelines for the Testing
of Chemicals, Section 4: Health Effects Test No. 417: Publication date: 23 Jul
2010.
OECD, 453 (Adopted September 7, 2009). OECD Guideline for the Testing of
Chemicals, COMBINED Chronic Toxicity/Carcinogenicity Studies. Available
from: <http://www.oecd-ilibrary.org/docserver/download/fulltext/9745301e.
pdf?expires=1348710784&id=id&accname=freeContent&checksum=B952BFD6
EE1A7D91C0FA5FC33797F237>.
Petersen et al, 1996. A 2-year comparison study of Crl:CD BR and Hsd:Sprague-
Dawley SD rats. Fund. Appl. Toxicol. 33, 196–211.
Richard, S., Moslemi, S., Sipahutar, H., Benachour, N., Seralini, G.E., 2005. Differential
effects of glyphosate and roundup on human placental cells and aromatase.
Environ. Health Perspect. 113, 716–720.
Ridley, W.P., Sidhu, R.S., Pyla, P., Nemeth, M.A., Breeze, M.L., Astwood, J.D., 2004.
Comparison of the nutritional proﬁle of glyphosate-tolerant corn event NK603
with that of conventional corn (Zea mays L.). J. Agric. Food Chem. 50, 7235–
7243.
Sakamoto, Y., Tada, Y., Fukumori, N., Tayama, K., Ando, H., Takahashi, H., Kubo, Y.,
Nagasawa, A., Yano, N., Yuzawa, K., Ogata, A., 2008. A 104-week feeding study of
genetically modiﬁed soybeans in F344 rats. J. Food Hygienic Soc. Jpn. 49 (4),
272–282.
Séralini, G.-E., Cellier, D., de Vendomois, J.S., 2007. New analysis of a rat feeding
study with a genetically modiﬁed maize reveals signs of hepatorenal toxicity.
Arch. Environ. Contam. Toxicol. 52, 596–602.
Séralini, G., Clair, E., Mesnage, R., Gress, S., Defarge, N., Malatesta, M., Hennequin, D.,
de Vendômois, J.S., 2012. Long term toxicity of a Roundup herbicide and a
Roundup-tolerant genetically modiﬁed maize. Food Chem. Tox. 50 (11), 4221–
4231.
Spiroux de Vendomois, J., Roullier, F., Cellier, D., Seralini, G.E., 2009. A comparison of
the effects of three GM corn varieties on mammalian health. Int. J. Biol. Sci. 5,
706–726.US EPA, 1993. Reregistration Eligibility Decision (RED) for glyphosate. US Environ-
mental Protection Agency, Ofﬁce of Pesticide Programs. EPA 738-R-93-014.
Available from: <http://www.epa.gov/oppsrrd1/REDs/old_reds/glyphosate.pdf>.
US EPA, 1998. Carcinogenicity. Health Effects Test Guidelines OPPTS 870.4200.
August 1998.
US EPA, 2009 a. Federal Register/Vol. 74, No. 115/Wednesday, June 17, 2009/Rules
and Regulations, 28616–28624.
US EPA, 2009b. Federal Register/Vol. 74, No. 71/Wednesday, April 15, 2009/Notices,
17579.
US EPA, 2011. May 10. Memorandum. Glyphosate – Review of the Technical
Response Submitted by the Glyphosate Consortium to the Report of the
Endocrine Disruptor Team for Test Order # EDAP-417300-229; 230; 240; 241;
244; 246; 247 and 248. DP Barcode: D386898.
WHO/FAO, 2004a. Pesticides residues in food – 2004. Report of the Joint Meeting of
the FAO Panel of Experts on Pesticide Residues in Food and the Environment
and the WHO Core Assessment Group on Pesticide Residues (JMPR). Rome,
Italy, 20–29 September 2004. FAO Plant Production And Protection Paper 178.
World Health Organization and Food and Agriculture Organization of the
United Nations. Rome, Italy. Available from: <http://www.fao.org/ag/agp/agpp/
Pesticid/JMPR/DOWNLOAD/2004_rep/report2004jmpr.pdf>.
WHO/FAO, 2004b. Pesticides residues in food – 2004. Report of the Joint FAO/WHO
Meeting on Pesticide Residues. Part II: Toxicological Evaluations. Available
from: <http://whqlibdoc.who.int/publications/2006/9241665203_eng.pdf>.
Williams, A.L., DeSesso, J.M., 2010. Genetically-modiﬁed soybeans. A critical
evaluation of studies addressing potential changes associated with ingestion.
The Toxicologist. 114, 1, 1154. Annual Meeting of the Society of Toxicology Salt
Lake City, Utah March 7–11, 2010.
Williams, A.L., Watson, R.E., DeSesso, J.M., 2012. Developmental and reproductive
outcomes in humans and animals after glyphosate exposure: a critical analysis.
J. Toxicol. Environ. Health B 15 (1), 39–96. http://dx.doi.org/10.1080/
10937404.2012.632361.
Bruce Hammond PhD, DABT, ATS
Product Safety Center, Science Fellow and Biotech Toxicology Team Lead,
Monsanto Company Zone C1NA,
800 N. Lindbergh Blvd, St. Louis, MO, United States.
Tel.: +1 314 694 8482; fax: +1 314 694 5071.
E-mail address: bruce.g.hammond@monsanto.com
Daniel A. Goldstein MD, FRPCP (Canada), FAAP, FACMT
Senior Science Fellow and Lead, Medical Sciences and Outreach,
Monsanto Company Zone C3ND,
800 N. Lindbergh Blvd, St. Louis, MO, United States.
Tel.: +1 314 694 6469.
E-mail address: daniel.a.goldstein@monsanto.com
David Saltmiras PhD, DABT
Manager of Toxicology,
Monsanto Company Zone C1NA,
800 N. Lindbergh Blvd, St. Louis, MO, United States.
Tel.: +1 314 694 8856; fax: +1 314 694 5071.
E-mail address: david.a.saltmiras@monsanto.com
Available online 7 November 2012
